KR102406001B1 - Oral composition for effective prevention of calculus formation - Google Patents
Oral composition for effective prevention of calculus formation Download PDFInfo
- Publication number
- KR102406001B1 KR102406001B1 KR1020150162289A KR20150162289A KR102406001B1 KR 102406001 B1 KR102406001 B1 KR 102406001B1 KR 1020150162289 A KR1020150162289 A KR 1020150162289A KR 20150162289 A KR20150162289 A KR 20150162289A KR 102406001 B1 KR102406001 B1 KR 102406001B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- cationic polymer
- sequestering agent
- anionic
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title 1
- 239000003352 sequestering agent Substances 0.000 claims abstract description 53
- 125000000129 anionic group Chemical group 0.000 claims abstract description 46
- 229920006317 cationic polymer Polymers 0.000 claims abstract description 39
- 208000006558 Dental Calculus Diseases 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 229920000289 Polyquaternium Polymers 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 229920000688 Poly[(2-ethyldimethylammonioethyl methacrylate ethyl sulfate)-co-(1-vinylpyrrolidone)] Polymers 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940079886 disodium lauryl sulfosuccinate Drugs 0.000 claims description 4
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 235000011180 diphosphates Nutrition 0.000 claims description 3
- KHIQYZGEUSTKSB-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O KHIQYZGEUSTKSB-UHFFFAOYSA-L 0.000 claims description 3
- 239000001205 polyphosphate Substances 0.000 claims description 3
- 235000011176 polyphosphates Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims description 3
- 229940005740 hexametaphosphate Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 abstract description 12
- 229940034610 toothpaste Drugs 0.000 abstract description 12
- 230000001680 brushing effect Effects 0.000 abstract description 9
- 210000000214 mouth Anatomy 0.000 abstract description 8
- 229910019142 PO4 Inorganic materials 0.000 abstract description 6
- 239000000796 flavoring agent Substances 0.000 abstract description 6
- 235000019634 flavors Nutrition 0.000 abstract description 6
- 239000010452 phosphate Substances 0.000 abstract description 6
- 238000005187 foaming Methods 0.000 abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 23
- -1 polyethylene Polymers 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 5
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 5
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000007794 irritation Effects 0.000 description 4
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 4
- 235000019832 sodium triphosphate Nutrition 0.000 description 4
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005354 coacervation Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000013588 oral product Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- TXASKRGBMHFMPT-UHFFFAOYSA-O 1-methoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium-2-ol Chemical compound C1=[N+](C)C2=C3C=C4OCOC4=CC3=CC=C2C2=C1C(OC)=C(O)C=C2 TXASKRGBMHFMPT-UHFFFAOYSA-O 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- TYTGWHZODQKWEF-UHFFFAOYSA-N 1-o-dodecyl 4-o-sulfo butanedioate Chemical compound CCCCCCCCCCCCOC(=O)CCC(=O)OS(O)(=O)=O TYTGWHZODQKWEF-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SKIIKRJAQOSWFT-UHFFFAOYSA-N 2-[3-[1-(2,2-difluoroethyl)piperidin-4-yl]oxy-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound FC(CN1CCC(CC1)OC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CC2=C(CC1)NN=N2)F SKIIKRJAQOSWFT-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- NGWKGSCSHDHHAJ-YPFQVHCOSA-N Liquoric acid Chemical compound C1C[C@H](O)C(C)(C)C2CC[C@@]3(C)[C@]4(C)C[C@H]5O[C@@H]([C@](C6)(C)C(O)=O)C[C@@]5(C)[C@@H]6C4=CC(=O)C3[C@]21C NGWKGSCSHDHHAJ-YPFQVHCOSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229940071180 lauryl sulfosuccinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 음이온성 금속이온봉쇄제와 양이온성 고분자를 함유하는 치석 형성 억제용 구강용 조성물에 관한 것으로, 보다 구체적으로는 양치 과정 중에 포스페이트계 음이온 금속이온봉쇄제와 폴리쿼터늄계 양이온 고분자가 코아세르베이트를 형성함으로써 치아 표면에 부착되어 치석형성 억제성분인 음이온계 금속이온봉쇄제가 헹굼 후에도 구강 내에 오랫동안 잔류하도록 하는 구강용 조성물에 관한 것이다.
본 발명의 치석 형성 억제용 구강용 조성물은, 치아 표면의 치석 형성을 효과적으로 방지할 수 있고, 동시에 치약의 향미를 유지하며 기포력을 향상시킬 수 있다.The present invention relates to an oral composition for inhibiting calculus formation containing an anionic sequestering agent and a cationic polymer, and more specifically, a phosphate-based anionic sequestering agent and a polyquaternium-based cationic polymer coacervate during the brushing process. By forming, it is attached to the tooth surface and the anionic sequestering agent, which is a tartar formation inhibitory component, remains in the oral cavity for a long time even after rinsing.
The oral composition for inhibiting tartar formation of the present invention can effectively prevent tartar formation on the tooth surface, and at the same time maintain the flavor of the toothpaste and improve the foaming power.
Description
본 발명은 음이온성 금속이온봉쇄제와 양이온성 고분자를 함유하는 치석 형성 억제용 구강용 조성물에 관한 것으로, 보다 구체적으로는 양치 과정 중에 포스페이트계 음이온 금속이온봉쇄제와 폴리쿼터늄계 양이온 고분자가 코아세르베이트를 형성함으로써 치아 표면에 부착되어 치석형성 억제성분인 음이온계 금속이온봉쇄제가 헹굼 후에도 구강 내에 오랫동안 잔류하도록 하는 구강용 조성물에 관한 것이다.The present invention relates to an oral composition for inhibiting tartar formation containing an anionic sequestering agent and a cationic polymer, and more specifically, a phosphate-based anionic sequestering agent and a polyquaternium-based cationic polymer coacervate during the brushing process. By forming, it is attached to the tooth surface and the anionic sequestering agent, which is a tartar formation inhibitory component, remains in the oral cavity for a long time even after rinsing.
일반적으로 구강 질환은 구강에 살고 있는 각종 세균들에 의해 발생하며, 유해 구강 세균들이 획득 피막에서 음식물 등의 잔유물을 먹고 증식하여 프라그를 형성하고, 프라그는 타액이나 혈액내의 칼슘 및 마그네슘 등의 금속 이온과 결합하여 석회화된 치석을 형성하게 된다. 이러한 프라그와 치석은 치은염, 치주염 등과 같은 잇몸질환을 일으키며, 더 나아가 치아에 손상을 주게 된다. 규칙적인 칫솔질은 이들 침착물의 빠른 형성을 막는데 도움을 주지만, 규칙적인 칫솔질조차도 치아에 부착된 모든 결석 침착물을 제거하기에는 충분하지 않다. 그래서 프라그와 치석 형성 억제를 위해 물리적으로는 연마제를 사용하고 화학적으로는 항균제 및 금속이온봉쇄제를 사용한다. In general, oral diseases are caused by various bacteria living in the oral cavity, and harmful oral bacteria eat residues such as food from the acquired film and multiply to form plaque, which is formed by metal ions such as calcium and magnesium in saliva or blood It combines with calcified calculus to form. These plaques and tartar cause gum diseases such as gingivitis and periodontitis, and further damage the teeth. Although regular brushing helps prevent the rapid formation of these deposits, even regular brushing is not sufficient to remove all stone deposits adhering to the teeth. So, to suppress the formation of plaque and tartar, physically an abrasive is used, and chemically, an antibacterial agent and sequestering agent are used.
구강용 제품에 사용되는 연마제에는 탄산칼슘, 실리카, 수산화알루미늄, 인산칼슘, 베이킹소다, 폴리에칠렌 및 폴리염화비닐 등과 같은 고분자물질이 있고, 구강용 제품에 사용되는 항균제에는 염화세틸피리디늄, 염화헥살코늄, 염화벤잘코니움, 염화데카리늄, 클로로헥시딘, 트리클로산, 티몰, 이소프로필메칠페놀 및 염화알킬디아미노에칠글리산 등이 있으며, 금속이온봉쇄제로는 파이로포스페이트, 폴리포스페이트 및 폴리포스포네이트 등이 있다.Abrasives used in oral products include high molecular substances such as calcium carbonate, silica, aluminum hydroxide, calcium phosphate, baking soda, polyethylene and polyvinyl chloride, and antibacterial agents used in oral products include cetylpyridinium chloride, hexalkonium chloride , benzalkonium chloride, decarinium chloride, chlorhexidine, triclosan, thymol, isopropylmethylphenol, and alkyldiaminoethylglycic acid chloride, and sequestering agents include pyrophosphate, polyphosphate and polyphosphorus. phonate, etc.
위와 같이 치석 형성 억제를 위해 주로 금속이온봉쇄제가 사용되어 왔으나, 금속이온봉쇄제가 단독으로 사용될 경우에는 양치질을 하고 헹구면 구강에 잔류하지 않고 씻겨나가 치석 형성 억제 효능에 어느 정도 한계가 있었다. 또한, 치석 제거 효능을 높이기 위해 금속이온봉쇄제를 과량 첨가하였을 경우, 자극이 생길 수 있으며, 역한 맛 등으로 인해 사용감이 나빠질 수도 있다. As above, sequestering agents have been mainly used to inhibit the formation of tartar, but when the sequestering agent is used alone, it is washed away without remaining in the oral cavity after brushing and rinsing. In addition, when an excessive amount of a sequestering agent is added to increase the tartar removal efficacy, irritation may occur and the feeling of use may deteriorate due to a foul taste.
이에, 본 발명자들은 치약을 헹궈낸 후에도 금속이온봉쇄제를 구강 내에 오래 잔류시키기 위한 방법을 찾기 위하여 예의 노력한 결과, 기존의 음이온성 금속이온봉쇄제와 함께 양이온성 고분자를 함께 함유하는 구강용 조성물의 경우, 음이온과 양이온의 침전반응으로 코아세르베이트가 형성되어 치아에 더 많은 양의 음이온계 금속이온봉쇄제를 잔류시켜 치석 형성 억제에 효과적임을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have made diligent efforts to find a way to keep the sequestering agent in the oral cavity for a long time even after rinsing the toothpaste. In this case, it was confirmed that coacervate is formed by the precipitation reaction of anions and cations, thereby leaving a larger amount of anionic sequestering agent on the teeth to be effective in inhibiting the formation of calculus, and the present invention has been completed.
본 발명의 목적은 음이온성 금속이온봉쇄제 및 양이온성 고분자를 함유함으로써 이들의 코아세르베이션을 유도하고, 이로 인하여 음이온성 금속이온봉쇄제가 치아 표면에 잔류함으로써 치석 형성을 억제시키는 구강용 조성물을 제공하는 데 있다.An object of the present invention is to provide a composition for oral cavity that contains an anionic sequestering agent and a cationic polymer to induce their coacervation, thereby inhibiting the formation of tartar by the anionic sequestering agent remaining on the tooth surface is to do
상기 목적을 달성하기 위하여, 본 발명은 음이온성 금속이온봉쇄제 및 양이온성 고분자를 유효성분으로 함유하는 치석 형성 억제용 구강용 조성물을 제공한다.In order to achieve the above object, the present invention provides an oral composition for inhibiting the formation of calculus containing an anionic sequestering agent and a cationic polymer as active ingredients.
본 발명의 치석 형성 억제용 구강용 조성물은, 치아 표면의 치석 형성을 효과적으로 방지할 수 있고, 동시에 치약의 향미를 유지하며 기포력을 향상시킬 수 있다.The composition for oral cavity suppression of tartar formation of the present invention can effectively prevent the formation of tartar on the tooth surface, while maintaining the flavor of the toothpaste and improving the foaming power.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 가진다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is those well known and commonly used in the art.
본 발명의 시험예에서, 음이온성 금속이온봉쇄제 및 양이온성 고분자를 함유하는 구강용 조성물을 치아모사물질에 처리한 결과, 음이온성 금속이온봉쇄제 및 양이온성 고분자가 코아세르베이트 형태로 치아 표면에 잔류함으로써, 잔류하는 음이온성 금속이온봉쇄제가 치석 형성을 억제하는 효과를 나타내는 것을 확인할 수 있었다. In the test example of the present invention, as a result of treating the oral composition containing the anionic sequestering agent and the cationic polymer to the tooth mimic material, the anionic sequestering agent and the cationic polymer remained on the tooth surface in the form of coacervate By doing so, it was confirmed that the residual anionic sequestering agent exhibits the effect of suppressing the formation of calculus.
따라서, 본 발명은 일 관점에서, 음이온성 금속이온봉쇄제 및 양이온성 고분자를 유효성분으로 함유하는 치석 형성 억제용 구강용 조성물에 관한 것이고, 상기 음이온성 금속이온봉쇄제 및 양이온성 고분자는 서로 반응하여 치아 표면에서 코아세르베이트를 형성하는 것을 특징으로 할 수 있다. Accordingly, in one aspect, the present invention relates to an oral composition for inhibiting calculus formation containing an anionic sequestering agent and a cationic polymer as active ingredients, wherein the anionic sequestering agent and the cationic polymer react with each other It may be characterized in that it forms a coacervate on the tooth surface.
본 발명에 있어서, 상기 조성물은 계면활성제를 더 함유하는 것을 특징으로 할 수 있다.In the present invention, the composition may be characterized in that it further contains a surfactant.
"코아세르베이션(coacervation)"이란, 친수성 콜로이드 용액 속에서, 콜로이드 입자의 수화 감소 및 정전기적 요인에 의해, 분산매에서 농축된 콜로이드졸이 분리되어 가는 현상을 의미하며, 분리된 액상 중에서 한쪽 액상은 콜로이드 농도가 높고, 다른 쪽 액상은 콜로이드 농도가 낮아지게 된다. "코아세르베이트(coacervate)"란 음이온성 고분자 전해질과 양이온성 고분자 전해질이 특정 조건에서 혼합되었을 때의 코아세르베이션 현상으로 인해 형성되는 콜로이드 물질을 의미한다. "Coacervation" refers to a phenomenon in which a concentrated colloidal sol is separated from a dispersion medium due to reduced hydration of colloidal particles and an electrostatic factor in a hydrophilic colloidal solution, and one of the separated liquids is The colloidal concentration is high, and the colloidal concentration of the other liquid phase is low. "Coacervate" refers to a colloidal material formed due to a coacervation phenomenon when an anionic polyelectrolyte and a cationic polyelectrolyte are mixed under specific conditions.
본 발명의 구강용 조성물에 함유된 음이온성 금속이온봉쇄제는 양이온성 고분자와 이온결합하여 침전함으로써 코아세르베이트를 형성하고, 형성된 코아세르베이트는 치석 형성 억제 효과를 갖는 금속이온봉쇄제가 치아 표면에 오랫동안 잔류할 수 있도록 한다.The anionic sequestering agent contained in the oral composition of the present invention forms a coacervate by ionic bonding with a cationic polymer and precipitation, and the formed coacervate is a sequestering agent having an effect of inhibiting tartar formation on the tooth surface for a long time. let it be
본 발명에 있어서, 상기 음이온성 금속이온봉쇄제는 인산(phosphate)계 화합물인 것을 특징으로 할 수 있다. 음이온성 금속이온봉쇄제는 치석 형성에 중요한 영향을 미치는 금속이온을 킬레이팅(chelating)하여 치석 형성을 억제하는 물질로서, 인산계 화합물이 바람직하며, 헥사메타포스페이트(hexametaphosphate), 파이로포스페이트(pyrophosphate), 폴리포스페이트(polyphosphate), 및 이들의 염으로 이루어진 군에서 선택된 1종 이상일 수 있다. 상기 염은 1~4개의 알칼리금속 양이온과 음이온인 포스페이트계 화합물이 결합한 형태일 수 있으며, 구체적인 예로는 소듐 포스페이트(Sodium phosphate), 모노소듐 포스페이트(Monosodium phosphate), 디소듐 포스페이트(Disodium phosphate), 트리소듐 포스페이트(Trisodium phosphate), 소듐 트리폴리포스페이트(Sodium tripolyphosphate), 소듐 헥사메타포스페이트(Sodium hexametaphosphate), 테트라소듐 파이로포스페이트(Tetrasodium pyrophosphate), 소듐 엑시드 파이로포스페이트(Sodium acid pyrophosphate) 등이 있으나, 반드시 이에 한정되는 것은 아니다.In the present invention, the anionic sequestering agent may be characterized in that it is a phosphate-based compound. The anionic sequestering agent is a substance that inhibits the formation of calculus by chelating metal ions that have an important influence on the formation of calculus, and preferably a phosphate-based compound, hexametaphosphate, pyrophosphate ), polyphosphate, and may be at least one selected from the group consisting of salts thereof. The salt may be in a form in which 1 to 4 alkali metal cations and an anion, a phosphate-based compound, are combined, and specific examples include sodium phosphate, monosodium phosphate, disodium phosphate, tri Sodium phosphate (Trisodium phosphate), sodium tripolyphosphate (Sodium tripolyphosphate), sodium hexametaphosphate (Sodium hexametaphosphate), tetrasodium pyrophosphate (Tetrasodium pyrophosphate), sodium acid pyrophosphate (Sodium acid pyrophosphate), etc. It is not limited.
또한, 본 발명에 있어서, 상기 양이온성 고분자는 폴리쿼터늄(polyquaternium)계 화합물인 것을 특징으로 할 수 있다. 폴리쿼터늄계 화합물은 4차 암모늄 이온이 중심에 존재하는 고분자 화합물(중합체)을 의미하며, 바람직하게는 폴리쿼터늄-10, 폴리쿼터늄-6, 폴리쿼터늄-11로 이루어진 군에서 선택된 1종 이상일 수 있으나, 반드시 이에 한정되는 것은 아니다.In addition, in the present invention, the cationic polymer may be characterized in that the polyquaternium (polyquaternium)-based compound. The polyquaternium-based compound refers to a high molecular compound (polymer) having a quaternary ammonium ion at the center, and is preferably one selected from the group consisting of polyquaternium-10, polyquaternium-6, and polyquaternium-11. or more, but is not necessarily limited thereto.
또한, 본 발명에 있어서, 상기 구강용 조성물은 음이온성 금속이온봉쇄제 및 양이온성 고분자 외에도, 계면활성제를 더 함유하는 것을 특징으로 할 수 있다. 계면활성제의 구체적인 예로는, 글리시네이트계, 설페이트계, 설포석시네이트계, 사코시네이트계, 포스페이트계, 이세치오네이트계, 글루타메이트계, 타우레이트계 등의 음이온성 계면활성제나, 베타인, 설타인, 암포아세테이트계 등의 양쪽성 계면활성제, 폴리옥시에틸렌 소르비탄 지방산에스테르, 폴리옥시에틸렌(경화) 피마자유, 글리세린지방산에스테르, 솔비탄지방산에스테르, 자당지방산에스테르, 알킬올아미드, 알킬글루코시드 등의 비이온 계면활성제, N-알킬디아미노 에틸글리신 등의 양이온성 계면활성제 등이 있고, 바람직하게는 소듐 라우릴 설페이트(Sodium lauryl sulfate), 소듐 메칠 코코일 타우레이트(Sodium methyl cocoyl taurate), 및 디소듐 라우릴 설포석시네이트(Disodium lauryl sulfosuccinate)로 이루어진 군에서 선택된 1종 이상일 수 있으나, 반드시 이에 한정되는 것은 아니다.In addition, in the present invention, the composition for oral cavity may be characterized in that it further contains a surfactant in addition to the anionic sequestering agent and the cationic polymer. Specific examples of the surfactant include anionic surfactants such as glycinate, sulfate, sulfosuccinate, sarcosinate, phosphate, isethionate, glutamate, and taurate, betaine , sultaine, amphoteric surfactants such as amphoteric acetate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene (hardened) castor oil, glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, alkylolamide, alkylgluco Nonionic surfactants such as seed, cationic surfactants such as N-alkyldiamino ethylglycine, etc., preferably sodium lauryl sulfate, sodium methyl cocoyl taurate , And disodium lauryl sulfosuccinate (Disodium lauryl sulfosuccinate) may be at least one selected from the group consisting of, but is not necessarily limited thereto.
또한, 본 발명에 있어서, 상기 음이온성 금속이온봉쇄제는 조성물 총 중량에 대하여 0.1~10.0중량%로 함유될 수 있고, 바람직하게는 1.0~7.0중량%, 더욱 바람직하게는 3.0~5.0중량%로 함유될 수 있다. 상기 음이온성 금속이온봉쇄제의 함량이 0.1중량% 미만이면 코아세르베이트가 형성되지 않고, 10.0중량%를 초과하면 향미와 기포력이 저하되고, 자극감이 심해지는 등 치약 사용감에 있어 좋지 않은 영향을 줄 수 있다.In addition, in the present invention, the anionic sequestering agent may be contained in an amount of 0.1 to 10.0% by weight, preferably 1.0 to 7.0% by weight, more preferably 3.0 to 5.0% by weight based on the total weight of the composition. may contain. If the content of the anionic sequestering agent is less than 0.1% by weight, coacervate is not formed, and if it exceeds 10.0% by weight, flavor and foaming power are reduced, irritation is severe, etc. have.
또한, 상기 양이온성 고분자는 조성물 총 중량에 대하여 0.01~0.50중량%로 함유될 수 있고, 바람직하게는 0.05~0.50중량%, 더욱 바람직하게는 0.10~0.50중량%로 함유될 수 있다. 상기 양이온성 고분자의 함량이 0.01중량% 미만이면 코아세르베이트가 형성되지 않고, 0.50중량%를 초과하면 치약내 점도가 높아 사용하기에 불편할 수 있다.In addition, the cationic polymer may be contained in an amount of 0.01 to 0.50% by weight, preferably 0.05 to 0.50% by weight, more preferably 0.10 to 0.50% by weight based on the total weight of the composition. If the content of the cationic polymer is less than 0.01% by weight, coacervate is not formed, and if it exceeds 0.50% by weight, the viscosity in the toothpaste is high, which may be inconvenient to use.
또한, 본 발명에 있어서, 상기 음이온성 금속이온봉쇄제와 양이온성 고분자는 0.2:1~1000:1의 중량비로 혼합되어 함유될 수 있고, 바람직하게는 10:1~100:1, 더욱 바람직하게는 30:1~50:1의 중량비로 혼합되어 함유될 수 있다. 음이온성 금속이온봉쇄제의 분자량이 상대적으로 작기 때문에, 양이온성 고분자보다 높은 비율로 혼합하는 것이 바람직하다. 상기 음이온성 금속이온봉쇄제와 양이온성 고분자의 혼합 비율이 0.2:1 미만이거나 1000:1 초과이면 코아세르베이트가 형성되기 어려울 수 있다.In addition, in the present invention, the anionic sequestering agent and the cationic polymer may be mixed and contained in a weight ratio of 0.2:1 to 1000:1, preferably 10:1 to 100:1, more preferably may be mixed and contained in a weight ratio of 30:1 to 50:1. Since the molecular weight of the anionic sequestering agent is relatively small, it is preferable to mix it in a ratio higher than that of the cationic polymer. If the mixing ratio of the anionic sequestering agent and the cationic polymer is less than 0.2:1 or more than 1000:1, it may be difficult to form coacervate.
본 발명의 구강용 조성물은 그 제형에 있어서 특별히 한정되지 않으며, 구체적인 예를 들면, 치약, 구강용 세정제, 구강용 청정제, 껌, 캔디류, 구강스프레이, 구강양치액, 치아 미백제 등의 제형을 가질 수 있다.The composition for oral use of the present invention is not particularly limited in its formulation, and specific examples thereof include toothpaste, oral cleaning agent, oral freshener, gum, candy, oral spray, oral gargle, tooth whitening agent, etc. formulations may have. .
본 발명의 구강용 조성물은 제형 및 사용 목적에 따라 통상적으로 사용하는 연마제, 습윤제, 보조 기포제, 결합제, 감미제, pH 조절제, 방부제, 약효성분, 향료, 증백제, 색소, 용제 등을 함유할 수 있다.The composition for oral use of the present invention may contain conventionally used abrasives, wetting agents, auxiliary foaming agents, binders, sweeteners, pH adjusters, preservatives, medicinal ingredients, fragrances, brighteners, pigments, solvents, etc. depending on the formulation and purpose of use. .
상기 연마제로는 침강실리카, 실리카겔, 지르코늄실리케이트, 인산일수소칼슘, 무수인산일수소칼슘, 함수알루미나, 경질탄산칼슘, 중질탄산칼슘, 칼슘피로인산염, 불용성메타인산염, 알루미늄실리케이트 등을 사용할 수 있다.As the abrasive, precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, anhydrous calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, aluminum silicate, etc. can be used.
상기 습윤제로는 농글리세린, 글리세린, 소르비톨수용액, 비결정성 소르비톨수용액, 폴리에틸렌글리콜류, 프로필렌글리콜 등을 사용할 수 있다.As the wetting agent, concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols, propylene glycol, and the like can be used.
상기 보조 기포제로는 알킬황산나트륨, 라우릴 황산나트륨, 자당지방산에스테르, 소르비탄지방산에스테르 등의 음이온 및 비이온 계면 활성제를 사용할 수 있다.As the auxiliary foaming agent, anionic and nonionic surfactants such as sodium alkyl sulfate, sodium lauryl sulfate, sucrose fatty acid ester, and sorbitan fatty acid ester may be used.
상기 결합제로는 카르복시메틸셀룰로오스나트륨, 카라기난, 잔탄검, 히드록시에틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 구아검, 젤란검, 카보머, 펙틴, 폴리비닐피롤리돈, 카르복시비닐폴리머, 알긴산나트륨, 라포나이트, 카르복시메틸셀룰로오스나트륨, 잔탄검 등을 사용할 수 있다.The binder includes sodium carboxymethylcellulose, carrageenan, xanthan gum, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, guar gum, gellan gum, carbomer, pectin, polyvinylpyrrolidone, carboxyvinyl polymer , sodium alginate, laponite, sodium carboxymethylcellulose, xanthan gum, etc. can be used.
상기 감미제로는 삭카린나트륨, 수크랄로스, 말티톨, 아스파탐, 에리스리톨, 자일리톨, 감초산, 사카린나트륨 등을 사용할 수 있고, 상기 방부제로는 안식향산, 메틸파라벤, 프로필파라벤, 안식향산나트륨, 파라옥시안식향산에스테르 등을 사용할 수 있다. 또한, 상기 향료로는 페퍼민트 오일, 스페아민트 오일, 멘톨 등을 단독 또는 혼합하여 사용할 수 있고, 상기 pH 조절제로는 인산나트륨, 인산이나트륨, 구연산, 트리에탄올아민 등을 사용할 수 있다.As the sweetener, sodium saccharin, sucralose, maltitol, aspartame, erythritol, xylitol, licoric acid, sodium saccharin, etc. can be used, and the preservative includes benzoic acid, methylparaben, propylparaben, sodium benzoate, paraoxybenzoic acid ester, and the like. can be used In addition, as the fragrance, peppermint oil, spearmint oil, menthol, etc. may be used alone or in combination, and as the pH adjusting agent, sodium phosphate, disodium phosphate, citric acid, triethanolamine, and the like may be used.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
[[ 실시예Example 1~9 및 1-9 and 비교예comparative example 1~3의 제조] Preparation of 1-3]
본 발명의 구강용 조성물의 코아세르베이트 생성 정도 및 잔류 정도를 테스트하기 위해, 정제수, 음이온성 금속이온봉쇄제(소듐헥사메타포스페이트, 테트라소듐파이로포스페이트, 소듐트리폴리포스페이트), 양이온성 고분자(폴리쿼터늄-10, 폴리쿼터늄-6, 폴리쿼터늄-11), 계면활성제(소듐라우릴설페이트, 소듐메칠코코일타우레이트, 디소늄라우릴설포석시네이트)를 주요 구성성분으로 하여, 하기 표 1의 구성과 같이 실시예 1 내지 9, 및 비교예 1 내지 3을 각각 총 중량이 100g이 되도록 제조하였다.In order to test the degree of coacervate production and residual degree of the oral composition of the present invention, purified water, anionic sequestering agents (sodium hexametaphosphate, tetrasodium pyrophosphate, sodium tripolyphosphate), cationic polymer (polyquaternium) -10, polyquaternium-6, polyquaternium-11), surfactant (sodium lauryl sulfate, sodium methylcocoyl taurate, disonium lauryl sulfosuccinate) as main components, As in the configuration, Examples 1 to 9 and Comparative Examples 1 to 3 were prepared so that the total weight was 100 g, respectively.
100To
100
100To
100
100To
100
100To
100
100To
100
100To
100
100To
100
100To
100
포스페이트Sodium Hexameta
phosphate
포스페이트Sodium Tripoly
phosphate
설페이트Sodium Lauryl
sulfate
타우레이트Sodium Methyl Cocoil
taurate
설포석시네이트Disodium Lauryl
sulfosuccinate
[[ 시험예test example 1] 코아세르베이트 생성 정도 측정 1] Measurement of coacervate production level
실시예 1 내지 9 및 비교예 1 내지 3의 샘플을 취하여, 각각에 정제수 첨가 비율을 점차 높이고, 샘플의 비율은 점차 낮추어가며 하기 표 2에 나타난 바와 같이 희석비율을 조정하되, 총 중량은 3g을 유지하도록 하였다. UV spectroscopy를 이용하여 희석된 각 샘플의 투명도(%)를 측정한 후, 그 결과를 표 2에 나타내었다. 투명도가 낮을수록 코아세르베이트가 많이 형성된 것으로 판단하였다.Taking the samples of Examples 1 to 9 and Comparative Examples 1 to 3, gradually increasing the addition ratio of purified water to each, and adjusting the dilution ratio as shown in Table 2 below while gradually decreasing the ratio of the sample, but the total weight was 3 g was made to keep. After measuring the transparency (%) of each diluted sample using UV spectroscopy, the results are shown in Table 2. It was determined that the lower the transparency, the more coacervate was formed.
상기 표 2에 나타난 바와 같이, 양이온성 고분자를 함유하지 않은 비교예 1의 경우 코아세르베이트가 형성되지 않았고, 음이온성 금속이온봉쇄제와 함께 양이온성 고분자를 함유하나, 계면활성제를 함유하지 않는 실시예 1의 경우, 희석 조건에 따라 코아세르베이트 생성 정도의 차이를 보였다. 또한, 음이온성 금속이온봉쇄제, 양이온성 고분자, 및 계면활성제를 함유하는 용액이 희석됨에 따라 코아세르베이트가 더 많이 형성되다가 어느 지점을 넘어서면 다시 코아세르베이트가 형성되지 않는 것을 확인할 수 있었다. 이로부터, 코아세르베이트 형성을 위해서는 적절한 희석비율이 중요함을 확인할 수 있었다.As shown in Table 2, in the case of Comparative Example 1 not containing the cationic polymer, coacervate was not formed, and the cationic polymer was contained together with the anionic sequestering agent, but the surfactant was not contained in Example 1 In the case of , there was a difference in the degree of coacervate production according to the dilution conditions. In addition, as the solution containing the anionic sequestrant, cationic polymer, and surfactant was diluted, more coacervate was formed. From this, it was confirmed that an appropriate dilution ratio is important for coacervate formation.
또한, 음이온성 금속이온봉쇄제 및 양이온성 고분자와 함께, 치약 제형에서 필수요소인 기포 형성을 위한 계면활성제를 첨가한 경우, 양이온성 고분자의 종류(실시예 2, 5, 6 비교), 음이온성 금속이온봉쇄제의 종류(실시예 2, 3, 4 비교), 또는 계면활성제의 종류(실시예 2, 7, 8 비교)에 따라서 코아세르베이트 생성 정도에 차이가 있음을 확인할 수 있었고, 음이온성 금속이온봉쇄제의 함량(실시예 2, 9 비교)에 따라서도 코아세르베이트 생성 정도에 차이가 생기는 것을 확인할 수 있었다.In addition, when a surfactant for bubble formation, which is an essential element in toothpaste formulation, is added together with the anionic sequestering agent and cationic polymer, the type of cationic polymer (compared to Examples 2, 5, and 6), anionic It was confirmed that there was a difference in the degree of coacervate generation depending on the type of sequestering agent (compared to Examples 2, 3, and 4) or the type of surfactant (compared to Examples 2, 7, and 8), and anionic metal ions It was confirmed that there was a difference in the degree of coacervate production also depending on the content of the blocking agent (compared to Examples 2 and 9).
또한, 실시예 1 내지 9에 비해 음이온성 금속이온봉쇄제 및 양이온성 고분자의 혼합비율(중량비)이 30:1 보다 낮은 비교예 2나, 50:1 보다 높은 비교예 3의 경우, 30:1~50:1의 범위 내에 있는 실시예 1 내지 9에 비해 코아세르베이트가 잘 생성되지 않음을 알 수 있었다.In addition, compared to Examples 1 to 9, the mixing ratio (weight ratio) of the anionic sequestrant and the cationic polymer is 30:1 in Comparative Example 2 lower than 30:1 or Comparative Example 3 higher than 50:1, 30:1 It was found that the coacervate was not well produced compared to Examples 1 to 9, which were within the range of ~50:1.
[[ 시험예test example 2] 치아 표면의 2] of the tooth surface 금속이온봉쇄제sequestering agent 잔류량 측정 Residual amount measurement
상기 시험예 1에서 음이온성 금속이온봉쇄제, 양이온성 고분자, 및 계면활성제가 함유된 용액에서 코아세르베이트가 형성되는 것을 확인한 후, 형성된 코아세르베이트가 얼마나 치아 표면에 잔류하는지를 생체외 테스트(in vitro test)를 통해 측정하였다. After confirming that coacervate was formed in the solution containing the anionic sequestrant, cationic polymer, and surfactant in Test Example 1, an in vitro test was performed to determine how much coacervate remained on the tooth surface. was measured through
표 1과 같이 제조된 실시예 2, 7, 9 및 비교예 1의 용액을 10배 희석한 후, 치아모사물질인 하이드록시아파타이트 디스크(Clarkson Chromatography Products)에 자동칫솔질 기계인 V-8 크로스 브러싱 머신(V-8 Cross Brushing Machine®, Sabri, USA)을 이용하여 브러싱을 하였다. 하이드록시아파타이트 디스크간의 오차를 줄이기 위해 4개의 디스크를 사용하였고, 3분간 희석용액을 브러싱 머신으로 양치질을 구현한 후 5회 세척하였다. 이를 10회 반복한 후 하이드록시아파타이트에 부착된 코아세르베이트를 수산화나트륨 용액(0.3M)으로 녹인 후, 이온크로마토그래피법(Ion chromatography, Metrohm)을 이용하여 코아세르베이트 내에 잔류하는 음이온성 금속이온봉쇄제의 양을 측정한 결과를 표 3에 나타내었다. After the solutions of Examples 2, 7, 9 and Comparative Example 1 prepared as shown in Table 1 were diluted 10-fold, the hydroxyapatite disc (Clarkson Chromatography Products), which is a dental mimic material, was placed on a V-8 cross-brushing machine, an automatic toothbrushing machine. (V-8 Cross Brushing Machine®, Sabri, USA) was used for brushing. To reduce the error between the hydroxyapatite disks, 4 disks were used, and after brushing the teeth with a brushing machine with a diluted solution for 3 minutes, it was washed 5 times. After repeating this 10 times, the coacervate attached to hydroxyapatite was dissolved in sodium hydroxide solution (0.3M), and then the amount of anionic sequestering agent remaining in the coacervate using ion chromatography (Metrohm). The measurement results are shown in Table 3.
상기 표 3에 나타난 바와 같이, 양이온성 고분자가 없는 경우(비교예 1)보다 양이온성 고분자가 있는 경우(실시예 2, 7, 9) 음이온성 금속이온봉쇄제의 잔류량이 확연히 많음을 알 수 있었고, 계면활성제간 차이는 약간 있지만 크지 않았으며(실시예 2, 7 비교), 음이온성 금속이온봉쇄제의 함량이 증가된 경우에는 음이온성 금속이온봉쇄제의 잔류량이 유의적으로 증가함(실시예 2, 9 비교)을 확인할 수 있었다. As shown in Table 3, it was found that the residual amount of the anionic sequestering agent was significantly higher when the cationic polymer was present (Examples 2, 7, 9) than when the cationic polymer was absent (Comparative Example 1). , the difference between the surfactants was slightly but not large (compared to Examples 2 and 7), and when the content of the anionic sequestering agent was increased, the residual amount of the anionic sequestering agent was significantly increased (Example) 2, 9) could be confirmed.
[[ 실시예Example 10~11 및 10-11 and 비교예comparative example 4의 제조] 4 Manufacturing]
음이온성 금속이온봉쇄제 및 양이온성 고분자를 함유하는 코아세르베이트 용액을 치약 형태의 페이스트 제형에 함유시킨 실시예 10~11 및 비교예 4를 하기 표 4의 구성과 같이 제조하였다.Examples 10 to 11 and Comparative Examples 4 in which a coacervate solution containing an anionic sequestrant and a cationic polymer were contained in a toothpaste paste formulation were prepared as shown in Table 4 below.
[[ 시험예test example 3] 3] 치석형성tartar formation 억제효능 측정 Inhibitory efficacy measurement
시험예 1 및 시험예 2의 결과를 바탕으로, 음이온성 금속이온봉쇄제 및 양이온성 고분자를 함유하는 본 발명의 구강용 조성물이 치석 형성을 억제하는 효능을 갖는지 측정하였다. Based on the results of Test Examples 1 and 2, it was measured whether the oral composition of the present invention containing an anionic sequestering agent and a cationic polymer had the effect of inhibiting the formation of calculus.
먼저, 사포질한 유리막대를 패널로부터 얻은 침과 설탕을 첨가한 용액에 담근 후, 2일간 35도에서 숙성시켰다. 유리막대 표면에 프라그를 형성시킨 후 25%의 치약 슬러리 용액(비교예 4, 실시예 10, 11)과 칼슘클로라이드(1.5mM)로 구성된 결정화 용액에 유리막대를 담궈 밤새 보관한 후 다음 날 5초간 유리막대 세척 후 다시 치약 슬러리 용액과 결정화 용액에 담궈 보관하였다. 이를 2주간 반복하여 형성된 치석을 강산(1M HCl)과 강염기(1M KOH)로 녹인 후 이온크로마토그래피(Ion chromatography, Metrohm)를 이용하여 칼슘 함량을 분석하여, 그 결과를 하기 표 5에 나타내었다. 칼슘함량이 낮을수록 치석 형성 억제 능력이 좋다고 판단하였다. First, the sanded glass rod was immersed in a solution containing saliva and sugar obtained from the panel, and then aged at 35°C for 2 days. After forming plaque on the surface of the glass rod, immerse the glass rod in a crystallization solution consisting of 25% toothpaste slurry solution (Comparative Examples 4, 10, 11) and calcium chloride (1.5 mM) and store overnight, and then store for 5 seconds the next day. After washing the glass rod, it was stored by immersing it in the toothpaste slurry solution and the crystallization solution again. The calculus formed by repeating this for 2 weeks was dissolved with a strong acid (1M HCl) and a strong base (1M KOH), and then the calcium content was analyzed using ion chromatography (Metrohm), and the results are shown in Table 5 below. It was judged that the lower the calcium content, the better the ability to inhibit the formation of calculus.
칼슘 함량 분석 결과, 표 5에 나타난 바와 같이, 양이온성 고분자를 함유한 경우(실시예 10, 11), 함유하지 않은 경우(비교예 4)보다 칼슘 함량이 낮고, 음이온성 금속이온봉쇄제의 함량을 증가시킬수록(실시예 10, 11 비교) 칼슘 함량이 낮아지는 것을 확인할 수 있었다. As a result of the calcium content analysis, as shown in Table 5, when the cationic polymer was contained (Examples 10 and 11), the calcium content was lower than that of the case without it (Comparative Example 4), and the content of the anionic sequestering agent It was confirmed that the calcium content decreased as the increase (compared to Examples 10 and 11) increased.
[[ 시험예test example 4] 치약 4] toothpaste 사용감feeling 평가 evaluation
시험예 3의 치석 형성 억제력 측정 결과를 바탕으로, 치약의 사용감을 평가하였다. 상기 실시예 10, 실시예 11, 및 비교예 4를 각각 20명씩 사용하게 하였고, 2주 사용 후 설문 조사를 통해 향미, 기포력, 자극감, 전체적인 만족도를 평가하게 한 후, 그 결과를 표 6에 나타내었다. Based on the measurement result of the calculus formation inhibition of Test Example 3, the feeling of use of the toothpaste was evaluated. Each of Example 10, Example 11, and Comparative Example 4 was used by 20 people, and after two weeks of use, flavor, foaming power, stimulation, and overall satisfaction were evaluated through a questionnaire survey, and the results are shown in Table 6 indicated.
(1점 : 매우 불만족 / 2점 : 불만족 / 3점 : 보통 / 4점 : 만족 / 5점 : 매우 만족)(1 point: very dissatisfied / 2 points: dissatisfied / 3 points: average / 4 points: satisfied / 5 points: very satisfied)
표 6에 나타난 바와 같이, 양이온성 고분자가 함유된 조성물(실시예 10, 11)이 치약의 향미 및 자극감에 커다란 영향을 주지 않았고, 기포력에 있어서는 오히려 도움을 주는 것을 확인할 수 있었다.As shown in Table 6, it was confirmed that the compositions (Examples 10 and 11) containing the cationic polymer did not significantly affect the flavor and irritation of the toothpaste, but rather helped in the foaming power.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the content of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereby. something to do. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.
Claims (11)
상기 음이온성 금속이온봉쇄제는 헥사메타포스페이트, 파이로포스페이트, 폴리포스페이트, 및 이들의 염으로 이루어진 군에서 선택된 어느 1종 이상인 인산계 화합물이고,
상기 양이온성 고분자는 폴리쿼터늄-10, 폴리쿼터늄-6, 및 폴리쿼터늄-11로 이루어진 군에서 선택된 어느 1종 이상인 폴리쿼터늄계 화합물인 것을 특징으로 하는 치석 형성 억제용 구강용 조성물.As an oral composition for inhibiting calculus formation containing an anionic sequestering agent and a cationic polymer as active ingredients,
The anionic sequestering agent is any one or more phosphoric acid-based compounds selected from the group consisting of hexametaphosphate, pyrophosphate, polyphosphate, and salts thereof,
The cationic polymer is polyquaternium-10, polyquaternium-6, and polyquaternium-11, an oral composition for inhibiting tartar formation, characterized in that at least one polyquaternium-based compound selected from the group consisting of.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2015/012470 WO2016153144A1 (en) | 2015-03-20 | 2015-11-19 | Oral composition effective in inhibiting calculus formation |
| TW104139053A TWI721957B (en) | 2015-03-20 | 2015-11-25 | Oral composition for effective prevention of calculus formation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150038730 | 2015-03-20 | ||
| KR1020150038730 | 2015-03-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160112919A KR20160112919A (en) | 2016-09-28 |
| KR102406001B1 true KR102406001B1 (en) | 2022-06-08 |
Family
ID=57101899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150162289A Active KR102406001B1 (en) | 2015-03-20 | 2015-11-19 | Oral composition for effective prevention of calculus formation |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102406001B1 (en) |
| CN (1) | CN107205892B (en) |
| TW (1) | TWI721957B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102635197B1 (en) | 2018-10-18 | 2024-02-13 | (주)아모레퍼시픽 | Oral composition for effective prevention of biofilm formation |
| CN113648227A (en) * | 2021-08-24 | 2021-11-16 | 浙江大学 | Dental adhesion pretreatment agent based on cationic polymer-metal complex and use method thereof |
| CN113797140A (en) * | 2021-09-27 | 2021-12-17 | 广州市南方医康生物科技有限公司 | Whitening and tooth-protecting toothpaste prepared from fermented plant-based raw materials |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100758786B1 (en) * | 2006-02-16 | 2007-09-14 | 주식회사 엘지생활건강 | Capsule-containing Oral Composition |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892724A (en) * | 1988-05-09 | 1990-01-09 | The B. F. Goodrich Company | Tartar inhibiting oral compositions and method |
| DE69330797T2 (en) * | 1993-01-19 | 2002-05-23 | The Gillette Co., Boston | Mouthwash |
| US5820853A (en) * | 1997-03-27 | 1998-10-13 | The Procter & Gamble Company | Oral compositions forming a coacervate gel |
| ITMI20012322A1 (en) * | 2001-11-06 | 2003-05-06 | Perfetti Van Melle Spa | ORAL COMPOSITIONS SOLID ANTI-TARTAR AND ANTI-BACTERIAL PLATE, USEFUL AS ADJUVANTS IN ODONT-STOMATOLOGICAL HYGIENE |
| CN100531703C (en) * | 2002-10-04 | 2009-08-26 | 宝洁公司 | Oral compositions and use thereof |
| BR0315955A (en) * | 2002-11-21 | 2005-09-13 | Lg Household & Health Care Ltd | Dry Gum Safe Plasters |
| KR100561211B1 (en) * | 2003-10-31 | 2006-03-15 | 이재익 | Solid tooth whitening agent that stabilizes whitening ingredients |
| US20050196354A1 (en) * | 2004-03-03 | 2005-09-08 | Andre Soshinsky | Film compositions |
| DK1791791T3 (en) * | 2004-09-27 | 2019-08-26 | Special Water Patents B V | Methods and compositions for treating water |
| US9198448B2 (en) * | 2005-02-07 | 2015-12-01 | Intercontinental Great Brands Llc | Stable tooth whitening gum with reactive ingredients |
| KR101154935B1 (en) * | 2005-05-12 | 2012-06-13 | 주식회사 엘지생활건강 | Liquid-crystal type tooth whitener |
| JP2007084471A (en) * | 2005-09-21 | 2007-04-05 | Sunstar Inc | Composition for oral cavity and method of selecting product for oral cavity |
| KR101277276B1 (en) * | 2007-06-08 | 2013-06-20 | 주식회사 엘지생활건강 | Toothpaste with stabilized peroxide |
| KR100873274B1 (en) * | 2007-06-12 | 2008-12-11 | 주식회사 엘지생활건강 | Film Type Toothpaste Composition |
| TWM333174U (en) * | 2007-07-06 | 2008-06-01 | Qing-Xiu Cai | Apparatus for whitening teeth |
| KR101013803B1 (en) | 2008-11-11 | 2011-02-14 | (주)아모레퍼시픽 | Oral composition effective in preventing tartar formation |
| US9186642B2 (en) * | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
| DE102010062611A1 (en) * | 2010-12-08 | 2012-06-14 | Henkel Ag & Co. Kgaa | Oral and dental care and cleaning products with increased antibacterial effect II |
| CN102512335B (en) * | 2012-01-10 | 2013-07-17 | 广州薇美姿个人护理用品有限公司 | Whitening toothpaste suitable for evening and combined whitening toothpaste suitable for morning and evening |
| CN104853810B (en) * | 2012-12-18 | 2017-11-14 | 高露洁-棕榄公司 | Stable Metal Ion-Containing Compositions |
| CN104055682A (en) * | 2013-03-22 | 2014-09-24 | 苏州维蒂卡科技有限公司 | Oral care product |
-
2015
- 2015-11-19 KR KR1020150162289A patent/KR102406001B1/en active Active
- 2015-11-19 CN CN201580075837.5A patent/CN107205892B/en not_active Expired - Fee Related
- 2015-11-25 TW TW104139053A patent/TWI721957B/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100758786B1 (en) * | 2006-02-16 | 2007-09-14 | 주식회사 엘지생활건강 | Capsule-containing Oral Composition |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201634039A (en) | 2016-10-01 |
| CN107205892A (en) | 2017-09-26 |
| TWI721957B (en) | 2021-03-21 |
| KR20160112919A (en) | 2016-09-28 |
| CN107205892B (en) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2281546B1 (en) | Tooth sensitivity treatment compositions | |
| US20210236396A1 (en) | Silica Abrasives with High Stannous Fluoride Compatibility | |
| KR102406001B1 (en) | Oral composition for effective prevention of calculus formation | |
| EP2281547B1 (en) | Tooth sensitivity treatment compositions | |
| TWI552766B (en) | Oral care composition | |
| EP2281548B1 (en) | Tooth sensitivity treatment compositions | |
| US11304888B2 (en) | Oral care composition | |
| KR20180113471A (en) | Dentifrice composition | |
| CN115884813A (en) | Oral care compositions containing abrasive and cocamidopropyl betaine | |
| WO2016153144A1 (en) | Oral composition effective in inhibiting calculus formation | |
| JP6444620B2 (en) | Liquid oral composition | |
| JP7715481B2 (en) | Oral stain removal composition | |
| JP2021001152A (en) | Liquid oral composition | |
| JP2020097557A (en) | Oral composition | |
| HK1154208B (en) | Tooth sensitivity treatment compositions | |
| HK1154207B (en) | Tooth sensitivity treatment compositions | |
| HK1153948B (en) | Tooth sensitivity treatment compositions | |
| HK1154207A (en) | Tooth sensitivity treatment compositions | |
| HK1152646A (en) | Tooth sensitivity treatment compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20151119 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200724 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20151119 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211108 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220518 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220602 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220602 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |